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ENHANCED SENTINEL LYMPHOSCINTIGRAPHIC
MAPPING IN BREAST TUMOR USING THE GRADED
SHIELD TECHNIQUE
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Departments of Nuclear Medicine and 1Gastroenteric Surgery, Chung-Ho
Memorial Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
The graded shield technique was developed to increase the sentinel node detection rate by
improving lymphoscintigraphic image contrast. In a 6-month period, 50 women with clinical
suspicion of early stage breast cancer (T1 and T2 tumors) were enrolled in this study. The
patients had a mean age of 47.2 ±  10.3 years. A composite graded shield was constructed
using three concentric layers of leaded plastic measuring 3 cm, 5 cm, and 7 cm each in
diameter. The graded shield was designed with a movable Velcro backing for accurate
positioning over the injection site. Images were acquired with a vertical angle dual-head
gamma camera using an established injection procedure developed at our institution. The
rate of detection of sentinel lymph nodes using lymphoscintigraphic mapping improved from
74% (37/50 patients) to 96% (48/50) using the graded shield (p < 0.05). In addition to the
increased detection rate, our technique also increased the number of nodes detected and
improved visualization of the adjacent lymphatic basin. By enhancing nodal contrast, we
have demonstrated that the graded shield technique is an effective method for improving
the rate of sentinel node detection.
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Sentinel lymph node (SLN) biopsy was developed to
assess the axillary nodal status of patients with early
stage breast cancer; in current practice, axillary lymph
node dissection can be avoided in patients with
negative SLNs [1–3]. Lymphoscintigraphic mapping
is an essential part of radio-guided SLN biopsy and
could be used in preoperative localization of SLNs
within the entire lymphatic drainage basin. However,
high quantities of radioactivity at the primary injection
site create “shine through”, which hinders SLN
detection in lymphoscintigraphy [4]. In order to
decrease this interference, our approach was to
incorporate a graded shield to mask the activity at the
injected area and to enhance imaging of SLN drainage.
In our series of 50 patients, this technique improved
the rate of detection of SLNs.
MATERIALS AND METHODS
Patients
In a 6-month period from November 2001 to April
2002, 50 women with clinical suspicion of early stage
© 2003 Elsevier. All rights reserved.
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breast cancer (T1 and T2 tumors) were enrolled in this
prospective study. Patients had a mean age of 47.2 ±
10.3 years (range, 31–83 years) at the time of these
diagnostic investigations. The most common location
of the lump was in the outer upper quadrant of the
breast.
Graded shield design
We designed a composite graded shield composed of
three concentric layers of leaded plastic pads. These
pads, with diameters of 3 cm, 5 cm, and 7 cm, were
affixed to one another with rubber cement (Figure 1).
Each layer was 0.25 cm thick with a measured
attenuation factor of three for 140 keV gamma photons.
The graded shield was also designed with a movable
Velcro backing for easy positioning at the injection site
during imaging.
Lymphoscintigraphic protocol
Patients underwent lymphoscintigraphy between 16
and 18 hours prior to surgery. Patients were positioned
supine with arms raised. A dose of 11.1–22.2 MBq
(0.3–0.6 mCi) of 99mTc sulfur colloid was injected
without filtration (100–1,000 nm), in 0.4 mL to 1.0 mL
of saline, subdermally and peritumorally at the
palpable tumor or biopsy site. Using the graded shield,
30 10-second frames of dynamic scintigraphic images
were acquired immediately. Static scintigraphic images
(anterior and lateral views of 500 k counts) with and
without graded shields were obtained using a vertical
angle, dual-head gamma camera (Siemens E.CAM,
Siemens Medical Systems Inc., Hoffman Estates, IL,
USA). The distance between the gamma detectors and
the patient was about 15 cm to 20 cm. Focal
accumulations of nodal radioactivity in the axillary
basin distinct from the injection area were considered
to be SLNs.
Enhancement of SLN scintigraphic mapping
For independent evaluation of the outcomes, two sets
of static images with and without graded shields were
presented to two nuclear medicine specialists for
interpretation. The lymphoscintigraphy findings were
then tallied in one of three categories as “easy”,
“equivocal”, or “poor” identification. A note was made
of any additional SLNs detected and SLNs whose
identification was facilitated by the use of graded
shields. The exact location of SLNs was confirmed by
intraoperative gamma probe detection (neo2000®,
Neoprobe Corp., Dublin, OH, USA). The t test was
used for statistical analysis.
RESULTS
We confirmed that all SLNs identified on preoperative
l y m p h o s c i n t i g r a p h y  w e r e  c o n s i s t e n t  w i t h
intraoperative gamma probe findings. Diagnostic
results based on the 50 patients are summarized in
Figures 2 and 3. Figure 2 shows a 24% improvement in
the easily identified group using the graded shields.
However, even with the graded shields, two patients
had nodal activity poorly identified by preoperative
lymphoscintigraphy. Also, one case that was initially
categorized as easily identified became equivocally
identified when graded shields were applied. These
exceptional cases will be discussed in detail. By
Figure 1. The composite graded shield. (A) Three concentric,
leaded plastic pads, with diameters of 3 cm, 5 cm and 7 cm, form
the graded shield. (B) From the lateral view, each pad has equal
thickness with one-third-attenuation effect.
Figure 2. Comparison of sentinel lymph node (SLN) detection
rates in lymphoscintigraphic mapping with and without graded
shields.
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combining the easily and equivocally identified
groups, the total SLN detection rate increased from
74% (36/50 patients) to 96% (48/50 patients) with
graded shields (p < 0.05). The improvement in nodal
detection with graded shields is shown in Figures 4
and 5.
The shielding technique increased the total number
of SLNs detected in the “easy” and “equivocal” groups.
Although most of these patients had only one detected
node, additional nodal activities were identified in 12
patients when graded shields were used, as shown in
Figure 3. A typical clinical case for additional nodal
detection is presented in Figure 6. Graded shielding
improved not only detection of the total number of
SLNs, but also the delineation of adjacent lymphatic
tracts.
DISCUSSION
Most  invest igators  agree  that  preoperat ive
lymphoscintigraphic mapping can provide surgeons
with valuable information about the orientation of the
major lymphatic drainage basin from the tumor site
and the location of SLNs [5,6]. In certain cases, primary
lymphatic drainage is also found to internal mammary
nodes and other locations outside the axilla that can
only be identified by preoperative lymphoscintigraphy
[7]. Therefore, lymphoscintigraphy allows the surgeon
to plan the incision before use of an intraoperative
gamma probe [6]. The incision can be made based on
Figure 3. Comparison of the number of axillary sentinel lymph
nodes (SLNs) detected in lymphoscintigraphic mapping with or
without graded shields among the easily identified and equivocally
identified nodal groups.
Figure 4. Right breast tumor in a 56-year-old female. The
sentinel lymph nodes (SLNs; arrows) are more easily identified
with than without graded shields on lymphoscintigraphic mapping.
(A) Anterior view with a graded shield. (B) Anterior view
without shielding. (C) Right lateral view with a graded shield.
(D) Right lateral view without shielding.
Figure 5. Left breast tumor in a 52-year-old female. The equivocally
identified sentinel lymph nodes (SLNs; arrows) are easily identified
when graded shields are used. (A) Anterior view with a graded
shield. (B) Anterior view without shielding. (C) Left lateral view
with a graded shield. (D) Left lateral view without shielding.
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knowledge of the location and number of SLNs or
secondary nodes.
In published literature, investigators have
visualized SLNs with lymphoscintigraphy in 75% to
98% of patients [5]. Many technical factors, such as
particle size, dose and volume of radiopharmaceuticals,
injection site, and imaging parameters, can result in
different outcomes in identifying SLNs [4,6,8].
Optimizing the image acquisition time, shielding the
injection site from scattering, and acquiring at least
two imaging projections are necessary to ensure SLN
detection. Previous studies suggest that injection of a
combination of smaller radioisotope dose (0.1–0.3 mCi)
and volume (0.1–0.3 mL) may diminish the effect of
injection site scattering [9]. Low injection dose and/or
volume may be suitable for a single subdermal or
periareolar injection, but visualization of internal
mammary SLNs is improved with abundant injected
dose volume. Therefore, a modified combination of
peritumoral and subdermal injections is considered
optimal for lymphatic mapping [1,10]. A dose of
0.4 mCi to 1.0 mCi in a volume of saline is widely
accepted [11,12]. Using the shielding technique and an
adequate injection dose/volume improves imaging of
the lymphatic drainage basin and identification of SLNs
in breast cancer.
The ability to detect a focus of increased activity in
the presence of background activity is dependent on
many factors. These include the overall spatial
resolution of the imaging system, the amount of
scattered radiation in the image data, and the contrast
between the lesion and background activity [13]. The
attenuation effect of graded shields reduces the
scattered background radioactivity. Therefore, image
contrast is enhanced and detection of SLN activity and
delineation of the adjacent lymphatic drainage are
both improved. By visual comparison, using graded
shields increased the contrast between SLNs and
background radioactivity in 47 of our series of 50
patients.
Previously, we employed a square leaded rubber
pad of uniform thickness, but discovered that it
attenuated nearby SLNs as well as the injection activity,
resulting in false-negative results. In this series, the
most common location for the breast tumor was the
outer upper quadrant, and the axillary SLNs were
typically seen in the low axilla, as in a previous study
[12]. A shorter distance between the breast tumor and
axillary SLNs results in significant scattering from
injection activity. As an alternative, we designed a
graded shield to vary the attenuating factors around
the injected site and potential nearby SLNs. Thus, we
can avoid inappropriate shielding and optimize the
identification of SLNs, thereby improving the rate of
SLN detection.
As previous studies report, certain individuals
demonstrate variations in breast lymphatic drainage
secondary to age, previous operative scar, or tumor
location, which can result in difficulty in SLN
identification [3,6,12].  We encountered three
exceptional cases in our study. In two of these cases,
the SLNs remained in the “poor” identification
category even when the graded shield was used. One
of these patients was a young female with previous
scarring. The second was an older woman, and age
may have resulted in reduced local lymphatic function
of the breast. We consider these individual lymphatic
variations to be a challenge to SLN detection on
lymphoscintigraphy even with our graded shield
technique. Oddly, the third case had an SLN in the
“easy” identification category without shielding, but
which became “equivocal” with the graded shield. In
this rare case, the reverse of the desired effect may
have occurred because the SLN was located near the
Figure 6. Right breast tumor in a 31-year-old female. Additional
sentinel lymph nodes (SLNs; arrows) are visualized on
lymphoscintigraphic mapping with graded shields. (A) Anterior
view with a graded shield. (B) Anterior view without shielding.
(C) Right lateral view with a graded shield. (D) Right lateral view
without shielding.
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injection site and covered by the graded shield. To
address this potential pitfall, we intend to develop a
graded shield with a smaller diameter.
Preoperative lymphoscintigraphic mapping is
valuable in providing details of the lymphatic drainage
basin and location of SLNs for preoperative surgical
planning. Many technical factors contribute to the
different reported SLN detection rates. A graded shield
at the palpable tumor or biopsy site improves SLN
contrast in lymphoscintigraphy and is an effective
method to improve the accuracy of SLN detection.
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